z-logo
open-access-imgOpen Access
Higher Pentraxin‐3 Levels are Associated With Inflammation in Familial Mediterranean Fever
Author(s) -
Bulut Mesudiye,
Ceri Mevlut,
Unverdi Selman,
Altay Mustafa,
Senes Mehmet,
Ecemis Zafer Aydın,
Duranay Murat
Publication year - 2016
Publication title -
journal of clinical laboratory analysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.536
H-Index - 50
eISSN - 1098-2825
pISSN - 0887-8013
DOI - 10.1002/jcla.21966
Subject(s) - ptx3 , medicine , subclinical infection , familial mediterranean fever , fibrinogen , inflammation , gastroenterology , c reactive protein , erythrocyte sedimentation rate , immunology , disease
Background Circulating levels of Pentraxin‐3 (PTX3) have been shown to increase in several inflammatory conditions. However, there is no information about the levels of PTX3 in patients with familial Mediterranean fever (FMF). This study was designed to evaluate the serum PTX3 levels in patients with FMF during attack and free‐attack periods. Methods Twenty FMF patients in attack and free‐attack period, and 20 age‐, sex‐, and body mass index‐matched healthy controls were included in the study. Blood samples were obtained within the first 24 h of the attack period and between attacks, and levels of white blood cell, erythrocyte sedimentation rate, Fibrinogen, high sensitive CRP, and PTX3 were determined. Results PTX3 levels during the attack period were not significantly different from those in free‐attack patients (4.9 ± 4.6 ng/ml vs. 2.8 ± 1.4 ng/ml, P > 0.05). However, both attack and free‐attack patients had significantly higher PTX3 levels than healthy controls (4.9 ± 4.6 ng/ml vs. 1.8 ± 0.8 ng/ml, P < 0.001; 2.8 ± 1.4 ng/ml vs. 1.8 ± 0.8 ng/ml, P < 0.025, respectively). Conclusions PTX3 levels were not markedly affected from FMF attacks, but high level of PTX3 in free‐attack period of FMF patients shows ongoing subclinical inflammation. However, further studies are needed to determine its usefulness as a marker in clinical practice.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here